UBS Group
NEUP

UBS Group’s Neuphoria Therapeutics NEUP Stock Holding History

UBS Group’s Portfolio NEUP Stock Details NEUP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.43K Buy
2,316
+664
+40% +$2.81K ﹤0.01% 8441
2025
Q4 		$6.41K Sell
1,652
-516
-24% -$3.67K ﹤0.01% 8556
2025
Q3 		$25.6K Buy
+2,168
New +$20.1K ﹤0.01% 8004
2025
Q1 		– Sell
-2,978
Closed -$10.2K – 10930
2024
Q4 		$10.2K Buy
+2,978
New +$10.5K ﹤0.01% 8309
2024
Q3 		– Sell
-2,908
Closed -$26.8K – 10227
2024
Q2 		$26.8K Buy
2,908
+2,080
+251% +$22.7K ﹤0.01% 7121
2024
Q1 		$10.2K Buy
828
+801
+2,967% +$10.6K ﹤0.01% 7238
2023
Q4 		$487 Sell
27
-180
-87% -$5.14K ﹤0.01% 8638
2023
Q3 		$6.7K Buy
+207
New +$4.46K ﹤0.01% 7282
2023
Q1 		– Sell
-73
Closed -$4.05K – 10558
2022
Q4 		$4.05K Buy
73
+62
+564% +$5.38K ﹤0.01% 9397
2022
Q3 		$1K Buy
11
+6
+120% +$529 ﹤0.01% 10066
2022
Q2 		$0 Hold
5
– – ﹤0.01% 11072
2022
Q1 		$0 Sell
5
-81
-94% -$10.7K ﹤0.01% 11027
2021
Q4 		$13K Buy
+86
New +$13.2K ﹤0.01% 8480

Other funds holding NEUP

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.4% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

UBS Group's NEUP Position: Q1 2026 in Review

UBS Group increased its Neuphoria Therapeutics (NEUP) stake by 40% in Q1 2026, buying an estimated $2.81K and bringing the position to 2,316 shares worth $9.43K. The position accounts for ﹤0.01% of the portfolio, ranked #8441.

UBS Group first reported a position in NEUP in Q4 2021 and has held it in 13 quarters since. The position peaked at $26.8K in Q2 2024. 19 funds tracked by Wall St. Rank hold NEUP as of Q1 2026.

  • UBS Group held 2,316 shares of Neuphoria Therapeutics worth $9.43K as of Q1 2026.
  • UBS Group bought 664 Neuphoria Therapeutics shares in Q1 2026, an estimated $2.81K.
  • Neuphoria Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #8441 holding.
  • UBS Group first reported a position in Neuphoria Therapeutics in Q4 2021 and has held it in 13 quarters since.
  • UBS Group's Neuphoria Therapeutics position peaked at $26.8K in Q2 2024.
  • 19 funds tracked by Wall St. Rank held Neuphoria Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.